Pharmafile - Research and Development News
Pascal Soroit, the Chief Executive Officer of the Anglo-Swedish multinational AstraZeneca, has raised concerns that he is being underpaid, despite...
Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, according to the...
Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive non-small cell lung...
Sarepta Therapeutics has revealed that its therapy Exondys 51 (eteplirsen) has been slapped with a negative opinion by the European Medicines...
AstraZeneca has unveiled new Phase 3 data for its SGLT2 inhibitor Farxiga (dapagliflozin), showing with the drug demonstrating positive findings in...
To find out more, check out this week’s Top 10 most popular articles on Pharmafile.com now!
Shares in the Texas based biotech Molecular Templates have soared after the company announced that they would be collaborating with Japanese pharma...
Astellas has revealed new Phase 3 data for roxadustat in the treatment of chronic kidney disease (CKD) in patients with anaemia not on dialysis,...
Almirall has announced that the European Commission has approved its interleukin-23 (IL-23) inhibitor Ilumetri (tildrakizumab) for the treatment of...
The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with relapsed or...
